Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
CAS RN: 88416-50-6 | Product Number: D4160
Disodium Clodronate Tetrahydrate
Purity: >95.0%(T)
- Clodronic Acid Disodium Salt Tetrahydrate
Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
---|---|---|---|---|---|
1G |
$91.00
|
1 | 3 | ≥40 |
|
5G |
$311.00
|
1 | Contact Us | 24 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
Product Number | D4160 |
Purity / Analysis Method | >95.0%(T) |
Molecular Formula / Molecular Weight | CH__2Cl__2Na__2O__6P__2·4H__2O = 360.91 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image), 5G-Glass Bottle with Plastic Insert (View image) |
CAS RN | 88416-50-6 |
Related CAS RN | 22560-50-5 |
PubChem Substance ID | 253660294 |
Merck Index (14) | 2371 |
MDL Number | MFCD02940846 |
Appearance | White to Almost white powder to crystal |
Purity(Neutralization titration) | min. 95.0 % |
Water | 18.0 to 22.0 % |
NMR | confirm to structure |
HS Number | 2931.59.0080 |
References
- 1)Bisphosphonates: From bench to bedside
- 2)Computational insights into binding of bisphosphonates to farnesyl pyrophosphate synthase
- 3)Tumour macrophages as potential targets of bisphosphonates
- 4)Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach
- 5)Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft
- 6)Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages
- 7)Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects
Articles/Brochures
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.